User:Mr. Ibrahem/Cefoxitin

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Cefoxitin
Clinical data
Trade namesMefoxin, Renoxitin, others[1]
Other namesCephoxitin cefoxitin sodium
AHFS/Drugs.comMonograph
MedlinePlusa682737
License data
Pregnancy
category
  • AU: B1
Routes of
administration		Intravenous
Drug classCephamycin[2]
Legal status
Legal status
Pharmacokinetic data
Metabolismminimal
Elimination half-life41-59 min
Excretion85% urine
Identifiers
  • (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-
    8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-
    1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Chemical and physical data
FormulaC16H17N3O7S2
Molar mass427.45 g·mol−1
3D model (JSmol)
Melting point149 to 150 °C (300 to 302 °F) (dec.)
  • O=C2N1/C(=C(\CS[C@@H]1[C@]2(OC)NC(=O)Cc3sccc3)COC(=O)N)C(=O)O
  • InChI=1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1 checkY
  • Key:WZOZEZRFJCJXNZ-ZBFHGGJFSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Cefoxitin, sold under the brand name Mefoxin, is an antibiotic, used to treat kidney infections, bone infections, pelvic inflammatory disease, intra abdominal infections, pneumonia, and sepsis.[4][5] It is given slowly by injection into a vein.[4]

Common side effects include allergic reactions, pain at the site of injection, and diarrhea.[5] Other side effects may include Clostridioides difficile infection and bone marrow failure.[5][4] It is not known to be harmful in pregnancy and may be used when breastfeeding.[4] A lower dose may be needed in those with kidney problems.[5] It is a cephamycin; though often grouped with the second-generation cephalosporins.[2][5]

Cefoxitin was discovered in 1972 and approved for medical use in the United States in 1978.[5][2] It is available as a generic medication.[6][7] In the United Kingdom, ten doses of 2 grams cost the NHS just less than £300, as of 2021.[4] This amount in the United States costs about 110 USD.[8]

References[edit]

  1. ^ "Cefoxitin International". Drugs.com. 2 November 2020. Archived from the original on 1 March 2016. Retrieved 8 November 2020.
  2. ^ a b c Levy SB (2013-11-11). The Antibiotic Paradox: How Miracle Drugs Are Destroying the Miracle. Springer. ISBN 9781489960429. Archived from the original on 2021-11-01. Retrieved 2021-07-06.
  3. ^ "Cefoxitin- cefoxitin sodium powder, for solution". DailyMed. 10 June 2020. Archived from the original on 18 January 2021. Retrieved 8 November 2020.
  4. ^ a b c d e f g "5. Infection". British National Formulary (BNF) (82 ed.). London: BMJ Group and the Pharmaceutical Press. September 2021 – March 2022. p. 560. ISBN 978-0-85711-413-6.{{cite book}}: CS1 maint: date format (link)
  5. ^ a b c d e f g h "CefOXitin Monograph for Professionals". Drugs.com. Archived from the original on 19 January 2021. Retrieved 30 December 2021.
  6. ^ "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations". www.accessdata.fda.gov. Archived from the original on 2021-11-01. Retrieved 2017-05-04.
  7. ^ "Supplement Approval" (PDF). Food and Drug Administration. Department of Health and Human Services. Archived (PDF) from the original on 2021-04-05. Retrieved 2021-07-06.
  8. ^ "Cefoxitin Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 15 April 2021. Retrieved 30 December 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Cefoxitin&oldid=1097169925"